OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Opportunities and challenges following approval of resmetirom for MASH liver disease
Jeffrey V. Lazarus, Dana Ivancovsky‐Wajcman, Henry E. Mark, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3402-3405
Closed Access | Times Cited: 24
Jeffrey V. Lazarus, Dana Ivancovsky‐Wajcman, Henry E. Mark, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3402-3405
Closed Access | Times Cited: 24
Showing 24 citing articles:
Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Pojsakorn Danpanichkul, Kwanjit Duangsonk, Markos Kalligeros, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Flavonoids for gastrointestinal tract local and associated systemic effects: A review of clinical trials and future perspectives
Xiaopeng Li, Enjun Xie, Shumin Sun, et al.
Journal of Advanced Research (2025)
Open Access | Times Cited: 3
Xiaopeng Li, Enjun Xie, Shumin Sun, et al.
Journal of Advanced Research (2025)
Open Access | Times Cited: 3
Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Daniel Q. Huang, Vincent Wai‐Sun Wong, Mary E. Rinella, et al.
Nature Reviews Disease Primers (2025) Vol. 11, Iss. 1
Closed Access | Times Cited: 2
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 14
Pharmacotherapeutic options for metabolic dysfunction-associated steatotic liver disease: where are we today?
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
Tobias Puengel, Frank Tacke
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 9, pp. 1249-1263
Open Access | Times Cited: 8
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Laurent Castéra, William Alazawi, Elisabetta Bugianesi, et al.
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 1
Laurent Castéra, William Alazawi, Elisabetta Bugianesi, et al.
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 1
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD ) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH ): From the Growing Prevalence to Payors' Perspective
Zobair M. Younossi, Homie Razavi, Michael S. Sherman, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Zobair M. Younossi, Homie Razavi, Michael S. Sherman, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
A narrative review of lifestyle management guidelines for metabolic dysfunction-associated steatotic liver disease
Dana Ivancovsky‐Wajcman, Christopher J. Byrne, John Dillon, et al.
Hepatology (2024)
Open Access | Times Cited: 6
Dana Ivancovsky‐Wajcman, Christopher J. Byrne, John Dillon, et al.
Hepatology (2024)
Open Access | Times Cited: 6
Global Burden of Metabolic Dysfunction-Associated Liver Disease, 2010 to 2021☆
Gong Feng, Giovanni Targher, Christopher D. Byrne, et al.
JHEP Reports (2024) Vol. 7, Iss. 3, pp. 101271-101271
Open Access | Times Cited: 4
Gong Feng, Giovanni Targher, Christopher D. Byrne, et al.
JHEP Reports (2024) Vol. 7, Iss. 3, pp. 101271-101271
Open Access | Times Cited: 4
LIMA1 O‐GlcNAcylation Promotes Hepatic Lipid Deposition through Inducing β‐catenin‐Regulated FASn Expression in Metabolic Dysfunction‐Associated Steatotic Liver Disease
Fuji Yang, Yifei Chen, Guojun Zheng, et al.
Advanced Science (2025)
Open Access
Fuji Yang, Yifei Chen, Guojun Zheng, et al.
Advanced Science (2025)
Open Access
Resmetirom: The First Disease‐Specific Treatment for MASH
Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan
International Journal of Endocrinology (2025) Vol. 2025, Iss. 1
Open Access
Ali Mohamed Mousa, Mervat Mahmoud, Ghaida Mubarak AlShuraiaan
International Journal of Endocrinology (2025) Vol. 2025, Iss. 1
Open Access
Novel Thyroid Hormone Receptor-β Agonist TG68 Exerts Anti-Inflammatory, Lipid-Lowering and Anxiolytic Effects in a High-Fat Diet (HFD) Mouse Model of Obesity
Beatrice Polini, Caterina Ricardi, F. Di Lupo, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 580-580
Open Access
Beatrice Polini, Caterina Ricardi, F. Di Lupo, et al.
Cells (2025) Vol. 14, Iss. 8, pp. 580-580
Open Access
ASS1 is a hub gene and possible therapeutic target for regulating metabolic dysfunction-associated steatotic liver disease modulated by a carbohydrate-restricted diet
Shaojun Chen, Yanhua Bi, Lihua Zhang
Molecular Diversity (2025)
Closed Access
Shaojun Chen, Yanhua Bi, Lihua Zhang
Molecular Diversity (2025)
Closed Access
Best buy interventions to address the burden of steatotic liver disease
Jeffrey V. Lazarus, Henry E. Mark, Naim Alkhouri, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 11, pp. 975-977
Closed Access | Times Cited: 3
Jeffrey V. Lazarus, Henry E. Mark, Naim Alkhouri, et al.
The Lancet. Gastroenterology & hepatology (2024) Vol. 9, Iss. 11, pp. 975-977
Closed Access | Times Cited: 3
Incretin-based therapies for the treatment of obesity-related diseases
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, et al.
npj Metabolic Health and Disease (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Irene Caruso, Angelo Cignarelli, Gian Pio Sorice, et al.
npj Metabolic Health and Disease (2024) Vol. 2, Iss. 1
Open Access | Times Cited: 3
Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets
Shengying Qian, Xiaolin Wang, Yingfen Chen, et al.
Seminars in Liver Disease (2024)
Closed Access | Times Cited: 2
Shengying Qian, Xiaolin Wang, Yingfen Chen, et al.
Seminars in Liver Disease (2024)
Closed Access | Times Cited: 2
Hepatic thyroid hormone receptor‐β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction‐associated steatohepatitis
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Stergios A. Pοlyzos, Giovanni Targher
Diabetes Obesity and Metabolism (2024)
Closed Access | Times Cited: 2
Intelligent Liver Function Testing (iLFT): An Intelligent Laboratory Approach to Identifying Chronic Liver Disease
Jennifer Nobes, Damien Leith, Sava Handjiev, et al.
Diagnostics (2024) Vol. 14, Iss. 9, pp. 960-960
Open Access | Times Cited: 1
Jennifer Nobes, Damien Leith, Sava Handjiev, et al.
Diagnostics (2024) Vol. 14, Iss. 9, pp. 960-960
Open Access | Times Cited: 1
Enhanced hepatoprotective effects of empagliflozin and vitamin D dual therapy against metabolic dysfunction‐associated steatohepatitis in mice by boosted modulation of metabolic, oxidative stress, and inflammatory pathways
Wesam F. Farrash, Shakir Idris, Mohamed E. Elzubier, et al.
International Journal of Experimental Pathology (2024) Vol. 105, Iss. 6, pp. 219-234
Open Access | Times Cited: 1
Wesam F. Farrash, Shakir Idris, Mohamed E. Elzubier, et al.
International Journal of Experimental Pathology (2024) Vol. 105, Iss. 6, pp. 219-234
Open Access | Times Cited: 1
Circulating metabolites associated with steatotic liver disease and liver enzymes: a multi-platform population-based study
Yasir J. Abozaid, Ibrahim Ayada, Laurens A. van Kleef, et al.
Gastro Hep Advances (2024) Vol. 4, Iss. 2, pp. 100551-100551
Open Access
Yasir J. Abozaid, Ibrahim Ayada, Laurens A. van Kleef, et al.
Gastro Hep Advances (2024) Vol. 4, Iss. 2, pp. 100551-100551
Open Access
Assessing Quality of Ultrasound Attenuation Coefficient Results for Liver Fat Quantification
Giovanna Ferraioli, Laura Maiocchi, R. Graham Barr, et al.
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2171-2171
Open Access
Giovanna Ferraioli, Laura Maiocchi, R. Graham Barr, et al.
Diagnostics (2024) Vol. 14, Iss. 19, pp. 2171-2171
Open Access
EEF1A2 identified as a hub gene associated with the severity of metabolic dysfunction-associated steatotic liver disease
Jian Zhang, Huiwen Wang, Qianbing Wang, et al.
Mammalian Genome (2024) Vol. 36, Iss. 1, pp. 93-105
Closed Access
Jian Zhang, Huiwen Wang, Qianbing Wang, et al.
Mammalian Genome (2024) Vol. 36, Iss. 1, pp. 93-105
Closed Access
Discovery of ZG-2305, an Orally Bioavailable Factor Inhibiting HIF Inhibitor for the Treatment of Obesity and Fatty Liver Disease
Yue Wu, Zewei Zhang, Haiping Cai, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Yue Wu, Zewei Zhang, Haiping Cai, et al.
Journal of Medicinal Chemistry (2024)
Closed Access
Novel Therapies for Nonalcoholic Steatohepatitis (NASH) and Cardiovascular Risk Reduction
Tarun Biswas, Angelica Lehker, Debabrata Mukherjee
Cardiovascular & Haematological Disorders - Drug Targets (2024) Vol. 24, Iss. 4, pp. 211-217
Closed Access
Tarun Biswas, Angelica Lehker, Debabrata Mukherjee
Cardiovascular & Haematological Disorders - Drug Targets (2024) Vol. 24, Iss. 4, pp. 211-217
Closed Access
